Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Y-90 Radioembolization in Intrahepatic Cholangiocarcinoma
NCT03117855Phase 1Withdrawn
- Sponsor
- City of Hope
- Start
- Dec 2016
- Primary completion
- Jun 2019
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of capecitabine in intrahepatic cholangiocarcinoma (ICC), sponsored by City of Hope. Primary endpoint: Incidence of dose limiting toxicities at Day 45. Planned start Dec 2016; status: withdrawn.
02
Drugs
capecitabine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT03117855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03117855.